Acquisition Overview

On October 21, 2026, Mapmygenome announced that it has completed the acquisition of dnaPower Inc., a Vancouver‑based pioneer in personal genomics. The transaction, disclosed through a PRNewswire release, expands Mapmygenome’s North American presence and creates a market‑leading platform for DNA testing, gut microbiome health, longevity, and AI‑driven multi‑omics testing across Canada and the United States.

Strategic Highlights

  • Market Expansion: The acquisition merges dnaPower’s consumer reach with Mapmygenome’s global footprint, technology stack, and research‑and‑development pipeline, enabling rapid scaling of commercial operations in North America.
  • Integrated Longevity Engine: By combining multi‑omics analytics with CAP‑accredited clinical laboratory capabilities, the combined entity will launch new offerings in healthy aging, gut profiling, and epigenetic age assessment.
  • Centralized Operations: A dedicated processing hub in Vancouver will operate under CAP‑accredited and ISO‑certified protocols, leveraging the laboratory infrastructure acquired previously through Microbiome Insights in 2025.

Testing Suite

The unified platform will provide a comprehensive suite of services, including:

  • Advanced shotgun metagenomic sequencing and gut microbiome profiling.
  • Epigenetic biological‑age panels and longevity insights.
  • Whole‑genome and exome sequencing, pharmacogenetics, DNA wellness panels, and methylation testing.
  • Clinical bioinformatics and AI‑driven multi‑omics analytics.

Executive Commentary

Founder and CEO Anu Acharya stated that acquiring dnaPower is a pivotal step in scaling Mapmygenome’s North American operations and that the combined capabilities position the company to define the next frontier in microbiome, longevity, and precision health testing. Dr. Lois Nahirney, Founder and CEO of dnaPower, expressed that joining Mapmygenome unlocks an extraordinary growth chapter, providing the laboratory infrastructure needed to scale rapidly across the region.

Company Backgrounds

  • Mapmygenome is described as a global leader in personal genomics, longevity solutions, and precision medicine, leveraging AI‑driven multi‑omics and CAP‑accredited clinical laboratories to deliver actionable health insights.
  • dnaPower Inc., founded in 2008 and based in Vancouver, specializes in DNA‑based health, nutrition, fitness, methylation, and longevity insights for consumers and practitioners.
  • Microbiome Insights, a Mapmygenome subsidiary acquired in 2025, offers CAP‑accredited DNA, microbiome, and multi‑omics sequencing, analytics, and bioinformatics services.

Media Contact: anu@mapmygenome.ai